Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 16:15:100187.
doi: 10.1016/j.obpill.2025.100187. eCollection 2025 Sep.

How do patients choose between obesity medications: A thematic analysis

Alvin Mondoh  1   2   3 , Hilary Craig  1   2 , Michael Crotty  3 , Francisca Contreras  1   2 , Carel W le Roux  1   2
Affiliations

How do patients choose between obesity medications: A thematic analysis

Alvin Mondoh et al. Obes Pillars. .

Abstract

Introduction: The rising prevalence of obesity is of particular concern due to its association with a range of serious complications, including type 2 diabetes mellitus, cardiovascular diseases, and certain types of cancer. Obesity medications can control the disease but it is unclear how patients choose which medication to use.

Methods: A qualitative thematic analysis was conducted to investigate how patients select between obesity medications. Fifteen treatment naive adults with a body mass index ≥27 kg/m2 with at least one weight-related complications were recruited.

Results: The 5 major themes depicting how patients make selections included 1) Effectiveness of medication, 2) Information to make decisions, 3) Safety of medications, 4) Practicality and 5) Individual Strategies and Community Supports in Obesity Management. Safety concerns of side effects and long-term risks were perceived major barriers to initiating or adhering to pharmacotherapy.

Conclusion: In a situation where the medications are described as being free and readily available, patient preferences for obesity medications are shaped by treatment efficacy, safety, information provided by healthcare providers. To enhance adherence and improve patient outcomes, healthcare providers should focus on delivering clear, comprehensive information and fostering strong support systems for patients.

Keywords: Effectiveness; Obesity; Obesity medication; Safety; Type 2 diabetes; Weight loss.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Image 1
Graphical abstract
See this image and copyright information in PMC

References

    1. WHO Obesity and overweight [Internet] 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight Available from:
    1. Le Roux C., Mondoh A. Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play? Expet Opin Pharmacother. 2024;25(2):131–138. - PubMed
    1. Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. - PubMed
    1. Craig H.C., Walley D., le Roux C.W. What influences patient decisions when selecting an obesity treatment? Obesity Pillars. 2024;12 - PMC - PubMed
    1. Craig H.C., et al. Patient perspectives about treatment preferences for obesity with complications. Obesit Sci Pract. 2024;10(1) - PMC - PubMed

LinkOut - more resources